The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
what Ramy does people call it an alisic inhibitor it binds to mtor but it doesn't bind in the heart of Emptor right if the heart is where it does its phosphorilation reaction that's sort of like the central node of it it doesn't bind there it actually binds close and what it does it prevents certain substrates from getting to that kyese domain it kind of sterically blocks them from getting there
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so it doesn't fully inhibit all the activities of even mtor one
so for example in this case if the amino acid is like a baseball that's supposed to bind in the right inside the glove Romy by blocking that doesn't sit itself right in the heart of the glove it maybe binds outside the glove and closes the glove it shapes it changes the shape of the glove so that the intended target doesn't is that a good analogy it is now now the thing that binds in the glove here is ATP which is the phosphate donor and then the substrate let's say6 kind but you're you're exactly right right those things are ATP can get in there no problem it's small it can
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.